Research Papers:

Insulin and novel thioglycosides exert suppressive effect on human breast and colon carcinoma cells

Siddarth Agrawal _, Marta Wozniak, Mateusz Luc, Kinga Walaszek, Ewa Pielka, Wieslaw Szeja, Gabriela Pastuch-Gawolek, Andrzej Gamian and Piotr Ziolkowski

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:114173-114182. https://doi.org/10.18632/oncotarget.23170

Metrics: PDF 1131 views  |   HTML 2995 views  |   ?  


Siddarth Agrawal1, Marta Wozniak1, Mateusz Luc1, Kinga Walaszek1, Ewa Pielka1, Wieslaw Szeja2, Gabriela Pastuch-Gawolek2,3, Andrzej Gamian4 and Piotr Ziolkowski1

1Department of Pathology, Wroclaw Medical University, Wroclaw, Poland

2Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Silesian University of Technology, Gliwice, Poland

3Biotechnology Centre, Silesian University of Technology, Gliwice, Poland

4Department of Biochemistry, Wroclaw Medical University, Wroclaw, Poland

Correspondence to:

Siddarth Agrawal, email: [email protected]

Keywords: cancer therapy; thioglycosides; insulin; breast cancer; colon cancer

Received: September 05, 2017     Accepted: November 16, 2017     Published: December 11, 2017


The rationale for the implementation of novel therapies should be based on hallmarks of cancer. Two novel compounds labelled as thioglycoside A and B were designed and evaluated on breast and colon cancer cell lines. We assessed their cytotoxic effect after sensitizing cancer cells with insulin. In order to explore the underlying mechanisms, we performed tests to assess cell migration and motility, apoptosis, expression of glucose transporter 1 and proapoptotic proteins. Both compounds proved to have an antitumor effect which was significantly enhanced in combination with insulin. Linking glucose and anticancer agent presents an approach that exploits the Warburg effect. Targeting dysfunctional glycometabolism and increased glucose absorption is emerging as a promising anticancer strategy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23170